[Asia Economy Reporter Chunhee Lee] GemVax recently announced on the 18th that it has signed a contract with ICON, a global Contract Research Organization (CRO), for a Phase 2 clinical trial of Alzheimer's disease in the United States.
ICON is a global CRO based in Ireland that rapidly rose to become the third-largest CRO worldwide in revenue last year after acquiring PRA Health Sciences in the U.S. for approximately $12 billion (about 16 trillion KRW) through a merger and acquisition (M&A).
For the U.S. Phase 2 trial, GemVax is currently selecting institutions and undergoing Institutional Review Board (IRB) reviews at each site. Through this contract, they plan to proceed with rapid patient recruitment.
A GemVax representative stated, "It is true that the clinical trial progress has been delayed for various reasons," adding, "We plan to conduct the trial as quickly as possible through collaboration with ICON, which has become one of the global top 3 CROs through recent M&A."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
